Sun Pharmaceutical Industries’ Halol plant in Gujarat, which was cleared in June by the US drug regulator, has been undergoing a fresh inspection, sources claimed.
The company declined to comment on the matter. Analysts said that while it could be a surprise audit (given the plant’s history of regulatory issues), it could also be a pre-approval inspection (that usually happens before a product from that site is approved by the US drug regulator). Sources claimed a team of inspectors from the US Food and Drug Administration (USFDA) was at the facility to inspect the plant.
The company stock was down